COPD患者不同LAMA/LABA固定剂量组合的临床结局比较
该回顾性队列研究基于全国保险理赔数据库,纳入44,498例新使用GLY/IND、UMEC/VI或TIO/OLO的COPD患者,经倾向评分匹配和Cox回归分析发现,UMEC/VI或GLY/IND相比TIO/OLO的严重急性加重风险更低,心血管事件发生率组间相似但GLY/IND略低。
要点
- UMEC/VI与GLY/IND相比TIO/OLO可降低COPD严重急性加重风险。
- 三组心血管事件发生率总体相似,GLY/IND使用者略低于TIO/OLO。
- GLY/IND的心血管获益在缩短随访时间后消失,需进一步研究确认。
核心结论
- 接受UMEC/VI或GLY/IND治疗的COPD患者严重急性加重风险低于TIO/OLO使用者。
- 心血管事件发生率各组相似,但GLY/IND使用者略低于TIO/OLO使用者。
研究设计与样本
- 回顾性队列研究,基于全国保险理赔数据库。
- 纳入2015年1月1日至2019年6月30日期间新处方GLY/IND、UMEC/VI或TIO/OLO的≥40岁COPD患者,共44,498例。
- 采用倾向评分匹配(UMEC/VI与GLY/IND 1:1,UMEC/VI与TIO/OLO 2:1,GLY/IND与TIO/OLO 2:1)和Cox回归模型比较结局。
主要发现
- UMEC/VI vs TIO/OLO:严重急性加重率17.85 vs 29.32每100人年,HR 0.76(95%CI 0.68-0.84)。
- GLY/IND vs TIO/OLO:严重急性加重率15.54 vs 25.53每100人年,HR 0.77(95%CI 0.67-0.88)。
- GLY/IND使用者心血管事件风险 tended to lower than TIO/OLO,但缩短随访后差异消失。
临床怎么用
- 在COPD患者选择LAMA/LABA固定剂量组合时,可考虑UMEC/VI或GLY/IND以降低严重急性加重风险。
- 对于心血管事件风险需关注的患者,GLY/IND可能略有优势但证据尚不稳定。
局限性
- 回顾性研究设计可能受残余混杂影响。
- GLY/IND心血管获益在缩短随访后消失,需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Researchers have yet to obtain conclusive evidence differentiating among fixed-dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) for COPD in terms of real-world clinical outcomes. RESEARCH QUESTION: What are the differences between available LAMA/LABA FDCs in the risk of acute exacerbation (AE) and cardiovascular events? STUDY DESIGN AND METHODS: This retrospective cohort study based on a national insurance claims database included patients with COPD ≥ 40 years of age who were newly prescribed glycopyrronium (GLY)/indacaterol (IND), umeclidinium (UMEC)/vilanterol (VI), or tiotropium (TIO)/olodaterol (OLO) FDC between January 1, 2015, and June 30, 2019. Propensity score matching and Cox regression models were used to compare outcomes of AE and cardiovascular events associated with LAMA/LABA FDC treatment. RESULTS: Among the 44,498 patients identified and included, 15,586 received GLY/IND, 20,460 received UMEC/VI, and 8,452 received TIO/OLO. Baseline characteristics were well balanced after 1:1 matching of UMEC/VI and GLY/IND, 2:1 matching of UMEC/VI and TIO/OLO, and 2:1 matching of GLY/IND and TIO/OLO. Risk of severe AE was lower among patients treated with UMEC/VI or GLY/IND than among those who received TIO/OLO (UMEC/VI vs TIO/OLO: 17.85 vs 29.32 per 100 person-years; hazard ratio, 0.76; 95% CI, 0.68-0.84; GLY/IND vs TIO/OLO: 15.54 vs 25.53 per 100 person-years; hazard ratio, 0.77; 95% CI, 0.67-0.88). In addition, GLY/IND users tended to have a lower risk of cardiovascular events than TIO/OLO users, but the difference dissipated when restricting follow up to a shorter duration. INTERPRETATION: Our results revealed that the risk of severe AE was lower among patients with COPD receiving UMEC/VI or GLY/IND than among those receiving TIO/OLO, whereas the incidence of cardiovascular events was similar across groups but was slightly lower in GLY/IND users when compared with TIO/OLO users. Further research will be required to confirm these findings.
引用
- Weng, Wu, Wu, et al. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD. Chest. 2022. PMID: 36442662. doi:10.1016/j.chest.2022.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。